Floatz logo

Tolinapant

Recurrent Fallopian Tube Clear Cell Adenocarcinoma

National Cancer Institute (NCI)Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Recurrent Fallopian Tube Clear Cell Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
NRG Oncology
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2B

View all 27 →

Same molecule, other indications

Tolinapant is also rated in:

ovarian serous adenocarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
fallopian tube carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →